FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

neck this box if no longer subject
Section 16. Form 4 or Form 5
oligations may continue. See
etruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

5. Relationship of Reporting Person(s) to Issuer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

1. Name and Address of Reporting Person*  FLUKE JOHN M JR				2. Issuer Name and Ticker or Trading Symbol Athira Pharma, Inc. [ ATHA ]									5. Relationship of Reporting Person(s) to Issu (Check all applicable)  X Director 10% Own						
(Last) (First) (Middle) C/O ATHIRA PHARMA, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/15/2021													Other (specify below)	
18706 NORTH CREEK PARKWAY, SUITE 104				4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
Street) BOTHELL WA 98011													X Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(St	ate) (2	Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)		Date	ear)   E	2A. Deemed Execution Date, if any (Month/Day/Year)		Ti C	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an 5)				5. Amount of Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						С	ode	v	Amo	ount	(A) or (D)	Price	Trans	Reported Transaction(s) (Instr. 3 and 4)					
Common Stock			21				J <sup>(1)</sup>		3,	,000	D	\$0.00(1)	3,731		I			Fluke Capital Management, L.P. <sup>(2)(3)</sup>	
Stock		06/15/202	1			J <sup>(4)</sup> 1,000 A \$0.00 <sup>(4)</sup>				144,884		D							
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		(Instr.	of Deriv Secu Acqu (A) or Dispo of (D) (Instr	rative rities ired r osed ) : 3, 4	Ex (M	piratio	n Date ay/Year)		Ame Sec Und Der Sec 3 ar	Amount or Number or	Derivative Security (Instr. 5) Bend Own Folk Repp Tran (Inst		deriva Secur Benet Owne Follov Repor Trans	vative Ovarities Footicially Dired or Ovarited saction(s)		n: ct (D) direct	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	(Fin HIRA PHAI IORTH CREATE IN SECURITY (Instance)  Security (Instance)	(First) (NHIRA PHARMA, INC. IORTH CREEK PARKWAY  LL WA 9  (State) (Z  Table  Security (Instr. 3)  1 Stock  1 Stock  2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle)  HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivate (Month/Day/Year)  1 Stock 06/15/202  Table II - Derivate (e.g., pto 12 conversion or Exercise Price of Derivative (Month/Day/Year)  2. Conversion Onte (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)	(First) (Middle) HIRA PHARMA, INC. IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  1 Stock  06/15/2021  Table II - Derivative S (e.g., puts, code of Derivative Security  (Month/Day/Year)  2. (Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  4. Transaction Date (Month/Day/Year)  (Month/Day/Year)	(First) (Middle)  (First) (Middle)  HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  I Stock  06/15/2021  Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year)  2. Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year)  3. Date of E 06/15/2021  4. If Amend 24. Transaction Code (Instr. 8)	Athira Pharm  (First) (Middle) HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Securities  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  1 Stock  06/15/2021  Table II - Derivative Securities A (e.g., puts, calls, warra  2. Table II - Derivative Securities A (e.g., puts, calls, warra  2. Conversion or Exercise Price of Derivative Security  Security  2. Transaction Date (Month/Day/Year)  3. Date of Earliest 06/15/2021  4. If Amendment,  2. Transaction Date (Month/Day/Year)  Conversion or Exercise Price of Derivative Securities A (e.g., puts, calls, warra  2. Conversion On Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  3. Date of Earliest 06/15/2021  4. If Amendment,  5. No of Date (A) of Derivative Securities A (B) of Derivative Securities A (B) of Derivative Securities A (Conversion or Exercise Price of Derivative Securities A (B) of Derivative Securities A (B) of Derivative Securities A (Conversion or Exercise Price of Derivative Securities A (B) of Derivative Securities A (Conversion or Exercise Price of Derivative Securities A (B) of Derivative Securities A (Conversion or Exercise Price of Derivative Securities A (B) of Derivative Securities A (Conversion or Exercise Price of Derivative Securities A (B) of Derivative Securities A	Athira Pharma,  (First) (Middle)  HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Securities Ac  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  I Stock  06/15/2021  Table II - Derivative Securities Acq (e.g., puts, calls, warrants  2. Transaction Date if any (Month/Day/Year)  I Stock  06/15/2021  Table II - Derivative Securities Acq (e.g., puts, calls, warrants  2. Transaction Date if any (Month/Day/Year)  Office of Derivative Securities Acq (e.g., puts, calls, warrants)  Athira Pharma,  3. Date of Earliest Tran 06/15/2021  4. If Amendment, Date Execution Date, if any (Month/Day/Year)  Office of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  Office of Derivative Security (Instr. 3, 4 and 5)	Athira Pharma, Inc  (First) (Middle)  HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Securities Acquired (Month/Day/Year)  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, operivative Security  2. Transaction Date (e.g., puts, calls, warrants, operivative Securities Acquired (A) or Disposed of poly (Month/Day/Year)  2. Transaction Date (e.g., puts, calls, warrants, operivative Security)  3. Date of Earliest Transaction Date, if any (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, operivative Securities Acquired (A) or Disposed of poly (Month/Day/Year)  2. Date of Earliest Transaction Date, if any (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, operivative Securities Acquired (A) or Disposed of poly (Instr. 3, 4 and 5)  Date of Earliest Transaction Date (Instr. 3)  4. If Amendment, Date of O	Athira Pharma, Inc. [ A  A thira Pharma, Inc. [ A  Athira Pharma, Inc.	Athira Pharma, Inc. [ATHA]  (First) (Middle) HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disponent (Month/Day/Year)  Security (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  1. Stock  06/15/2021  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disponent (Month/Day/Year)  Table II - Derivative Securities Acquired, Disponent (Month/Day/Year)  Table II - Derivative Securities Acquired, Disponent (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disponent (Month/Day/Year)	Athira Pharma, Inc. [ ATHA ]  (First) (Middle)  HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of Month/Day/Year)  Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) 2. Transaction Date (e.g., puts, calls, warrants, options, converting Price of Derivative Security  2. Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converting of Date (month/Day/Year) (Month/Day/Year)  2. Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converting of Date (month/Day/Year) (Month/Day/Year) (Month/Day/Year)  2. Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converting of Date (month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  2. Transaction Date (e.g., puts, calls, warrants, options, converting and 5) (month/Day/Year)	Athira Pharma, Inc. [ATHA]  (First) (Middle) HIRA PHARMA, INC.  (ORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Security (Instr. 3)  2. Transaction (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  1. Stock  06/15/2021  2. Deemed Execution Date, if any (Month/Day/Year)  1. Stock  06/15/2021  3. Transaction Code (Instr. 5)  Code V Amount (A) or (D)  Code V Amount (A) or (D)  Table II - Derivative Securities Acquired, Disposed of, or Beroise of Code (Instr. 5)  Table II - Derivative Securities Acquired, Disposed of, or Beroise of Code (Instr. 6)  Stock  06/15/2021  3. Transaction Code (Instr. 6)  Code V Amount (A) or (D)  Table II - Derivative Securities Acquired, Disposed of, or Beroise of Code (Instr. 6)  Code V Amount (A) or (D)  Code V Amount (B) or (D)  Code V Amount (C)  Code (Instr. 3, 4  Code (Instr. 3,	(First) (Middle) HIRA PHARMA, INC.  IORTH CREEK PARKWAY, SUITE 104  LL WA 98011  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic Recursion Date (Month/Day/Year)  (Month/Day/Year)  1 Stock  06/15/2021  2 Tansaction Date (Month/Day/Year)  1 Stock  06/15/2021  2 Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  1 Stock  06/15/2021  2 Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  2 Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  2 Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  2 Table II - Derivative Securities Acquired, Disposed of, or Beneficial (E.g., puts, calls, warrants, options, convertible securities Acquired (Month/Day/Year)  2 Table II - Derivative Securities Acquired, Disposed of, or Beneficial (E.g., puts, calls, warrants, options, convertible securities Acquired (Month/Day/Year)  2 Table II - Derivative Securities Acquired (Month/Day/Year)  2 Table II - Derivative Securities Acquired (Month/Day/Year)  3 Tansaction Date (Nonth/Day/Year)  4 Tansaction Date (Nonth/Day/Year)  2 Tansaction Date (Nonth/Day/Year)  4 Tansaction Date (Nonth/Day/Year)  5 Number (Nonth/Day/Year)  6 Date Exercise Parkway, III (Month/Day/Year)  8 Date Exercise Expiration Date (Month/Day/Year)  8 Date Expiration Date (Month/Day/Year)  8 Date Expiration Date (Month/Day/Year)  9 Date Expiration Date (Month/Day/Year)  1 Title and Date (Month/Day/Year)  2 Title and Date (Month/Day/Year)  2 Title and Date (Month/Day/Year)  2 Title and Date (Month/Day/Year)  3 Title and Date (Month/Day/Year)  4 Title and Date (Month/Day/Year)  5 Date (Month/Day/Year)  6 Date (Month/Day/Year)	Athira Pharma, Inc.   ATHA	Athira Pharma, Inc. [ATHA]  At	Athira Pharma, Inc. [ATHA]  Athiral Pharma, Inc. [ATHA]  Athiral Pharma, Inc. [ATHA]	Athira Pharma, Inc. [ATHA]  (Check all applicable)  X Director Officer (give title below)  3. Date of Earliest Transaction (Month/Day/Year) 06/15/2021  4. If Amendment, Date of Original Filed (Month/Day/Year) (State)  (State)  (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3)  2. Transaction Date, (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  2. Transaction Date, (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  3. Securities Acquired (A) or Date, (Instr. 3)  4. Securities Acquired (A) or Date, (Month/Day/Year) (Month/Day/Year)  5. Amount of Securities Securities Securities Acquired (A) or Date, (Instr. 3)  5. Amount of Securities Securities Securities Acquired (A) or Date Securities	Athira Pharma, Inc. [ATHA]    Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   Check all applicable)   X Director   1 Officer (give title below)   Check all applicable)   Check all applicable)   Check all applicable   Check all applicable   Check all applicable)   Check all applicable   Check	Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) Athira Pharma, Inc. [ATHA] (Check all applicable) X Director 10% Own Officer (give title below)  Athira Pharma, Inc. [ATHA] (Check all applicable) Athira Pharma, Inc. [ATHA] (Month/Day/Year)  Athira Pharma, Inc. [ATHA]

## **Explanation of Responses:**

- 1. Fluke Capital Management, L.P. distributed these shares to its partners on a pro rata basis for no consideration (the "Distribution").
- 2. The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- 3. The Reporting Person is a director of Fluke Management Corp., which is the managing general partner of Fluke Capital Management, L.P. The Reporting Person is also a partner of Fluke Capital Management, L.P. By virtue of such relationships, Mr. Fluke may be deemed to have voting and investment power with respect to the shares held by Fluke Capital Management, L.P. and as a result may be deemed to have beneficial ownership of such shares
- 4. Acquisition by the Reporting Person pursuant to the Distribution.

## Remarks:

/s/ Glenna Mileson, attorneyin-fact on behalf of John M.

\*\* Signature of Reporting Person Date

06/16/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.